Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 2 · below the Ichimoku cloud · RSI 35 · MACD below its signal · 4% above its 52-week low
| 5.36 | 52-week high | +51.70% |
| 4.72 | Previous month high | +33.58% |
| 4.11 | Previous week high | +16.32% |
| 3.75 | Previous month low | +6.13% |
| 3.65 | R3 (classic) | +3.30% |
| 3.65 | R2 (classic) | +3.30% |
| 3.65 | R1 (classic) | +3.30% |
| 3.65 | Pivot | +3.30% |
| 3.65 | S1 (classic) | +3.30% |
| 3.65 | S2 (classic) | +3.30% |
| 3.65 | S3 (classic) | +3.30% |
| 3.65 | Previous day high | +3.30% |
| 3.65 | Previous day low | +3.30% |
| 3.53 | Price now | |
| 3.53 | Previous week low | −0.10% |
| 3.52 | 52-week low | −0.38% |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.5 | 18.2 | -21.0 | 6.6 | -0.7 | -7.9 | 1.6 | 14.5 | -13.1 | -9.6 | −18.9% | ||
| 2025 | 8.7 | -2.5 | -22.9 | 0.5 | -2.2 | 0.2 | -3.1 | 1.4 | -1.1 | -2.0 | 13.4 | 5.7 | −8.2% |
| 2024 | 14.4 | -10.0 | -2.3 | -10.0 | -4.8 | 100.8 | 18.7 | -33.8 | -10.4 | 5.4 | 8.6 | -18.4 | +13.6% |
| 2023 | -1.5 | -3.1 | -3.4 | 9.1 | -2.6 | -3.1 | -3.8 | -0.1 | -30.8 | -14.7 | 19.0 | -0.5 | −36.2% |
| 2022 | 42.6 | -11.7 | -14.9 | -60.8 | -5.6 | -10.8 | -8.7 | -5.3 | 14.2 | -6.9 | 2.7 | 2.3 | −65.8% |
| 2021 | -0.4 | 2.7 | -6.4 | -5.1 | -24.7 | 36.9 | −6.4% |
No insider transactions reported for MOLN.
Buy / hold / sell counts
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
None of the 29 investors followed here reported a position in MOLN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MOLN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades